Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-HTTRx in Patients With Early Manifest Huntington's Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by Isis Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Isis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT02519036
First received: August 1, 2015
Last updated: August 20, 2015
Last verified: August 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)